Inectolizumab with steroids for first attack of NMOSD
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a new drug called inectolizumab combined with steroids for people having their first attack of NMOSD, a rare autoimmune disease that can cause vision loss and paralysis. The goal is to see if this combination is safe and helps reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with NMOSD and tested positive for AQP4 antibodies.
- This is your first attack of NMOSD.
- You are between 18 and 65 years old.
- Your disability level is not too severe (can still walk with help).
- If you are able to have children, you must use effective birth control during the study.
- You have not used certain immune-suppressing drugs recently, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with NMOSD who have recently had an attack. It compares two ways of slowly reducing steroid treatment while also receiving an experimental drug called inebilizumab, to see which approach helps prevent future attacks better.
This trial studies whether inebilizumab can reduce illness activity in children with neuromyelitis optica spectrum disorder (NMOSD), a condition that can cause attacks affecting the eyes and spinal cord. It focuses on kids who have had recent relapses, meaning symptoms came back or worsened.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
This study tests a new treatment called CC-97540 (a type of CAR T-cell therapy) for people with neuromyelitis optica spectrum disorder (NMOSD), which is an autoimmune disease that affects the eyes and spinal cord. The goal is to see if this treatment is safe and tolerable.
This Phase 2 study tests inebilizumab in people with NMDA receptor encephalitis, an immune-related brain condition. It looks to see if adding this treatment after starting steroids (and possibly other first treatments) improves recovery and safety.
Hear when a new Neuromyelitis Optica trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.